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NEWS AND PERSPECTIVES
The discovery of the mechanism of RNA interfer-
ence (RNAi) for knockdown of gene expression
has spurred a variety of therapeutic applications.
An asset of using small interfering RNA (siRNA)
as therapeutics is their exquisite sequence-specific
mechanism of action. It seems possible that the
first RNAi therapy that could reach patients would
aim at a debilitating eye disease called age-related
macular degeneration, which afflicts 30–50 mil-
lion people globally; the reason being that siRNAs
can be delivered directly to the diseased tissue—
that is, literally injected into the eye. To minimize
systemic exposure and to make it less likely that
the drug will have unanticipated, harmful effects
elsewhere in the body, the therapeutic focus has
been on local delivery. The disease is triggered by
a protein called vascular endothelial growth factor
(VEGF) that promotes blood vessel growth. Too
much of this protein leads to the sprouting of 
excess blood vessels behind the retina. Macular
degeneration is induced by leakage of the blood
vessels, which causes clouding and frequently de-
stroys vision. The new RNAi drugs were supposed
to shut down VEGF expression or its receptor
(VEGFR1). However, recent evidence indicates that
the preclinical efficacy observed in mouse models
of macular degeneration probably results from
nonspecific side effects rather than RNAi-mediated
sequence-specific gene knockdown. Such non-
specific effects may trouble other RNAi therapeutic
applications.
The cellular mechanism of RNAi can be 
instructed to cleave specific mRNAs by addition
of manmade siRNAs of which the antisense/
guide strand has perfect sequence complemen-
tarity with the targeted mRNA. In our research to
develop gene therapy against human immuno-
deficiency virus type 1 (HIV-1), we observed im-
pressive and specific inhibition via the RNAi
mechanism. In fact, we documented that mutant
escape viruses are selected under RNAi pressure
with a single point mutation in the 19-nucleotide
target sequence, thus demonstrating the exqui-
site sequence-specificity of inhibition.1 Thera-
peutic application of “naked” siRNA molecules
remains a challenge because mammalian cells
do not spontaneously take up such molecules
without cell-permeating entities. Nevertheless,
siRNAs targeting the VEGF system that were in-
jected directly into an affected eye did reduce 
angiogenesis in preclinical studies with mice.2,3
Based on these promising preclinical results, clini-
cal trials have been approved that exploit RNAi
to shut down the VEGF signaling pathway that
promotes angiogenesis.
It is important to realize that although naked,
unmodified siRNAs can be injected directly into
the confined space of ocular tissue, there was 
little knowledge of how the siRNAs entered the
target cells. The assumption has been that the
siRNA enters an affected cell in some unexplained
way, where it has a highly specific impact in
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shutting down angiogenesis activity. Surprisingly,
the recent study by Kleinman et al4 indicates that
this assumption is not correct. These authors de-
scribe that the anti-angiogenesis effect can be in-
duced in the mouse model with unrelated siRNAs
that differ significantly in nucleotide sequence.
In their search for possible cell surface molecules
that could mediate this general siRNA effect, Toll-
like receptor 3 (TLR3) emerged as a possible can-
didate receptor. The siRNAs were indeed shown
to act through TLR3, an innate immune system
regulator present on the surface of many cell types.
No effect was scored in TLR3-deficient mice and
addition of soluble TLR3 protein reversed the in-
hibitory siRNA effects. Thus, the siRNAs operate
without being taken up by the cell! Any double-
stranded RNA of at least 21 nucleotides can 
bind directly to TLR3, inducing receptor dimer-
ization and an intracellular signaling pathway
that eventually leads to activation of the nuclear
factor-κB transcription factor that, among other
things, activates expression of interferon-γ and
interleukin-12. These cytokines are the likely in-
ducers of the anti-angiogenesis program. On a pos-
itive note, it was proposed that generic siRNAs
could perhaps be harnessed to treat various dis-
eases linked to angiogenic disorders that affect
8% of the world’s population.4
This result indicates that the development of
safe siRNA-based therapies might be more chal-
lenging than was initially anticipated. These sur-
prising findings also reemphasize the importance
of appropriate controls in RNAi experiments. 
It is not unusual that testing of a single siRNA
candidate inhibitor should be accompanied by
multiple siRNA controls to test for sequence-
specificity, off-target effects on other mRNAs and
TLR3-mediated cytokine responses. At least such
nonspecific effects are becoming better defined in
molecular terms, which should help in the design
of more rigorous experimental standards. Clearly,
this work does not relate to other therapeutic ap-
proaches that use delivery methods, e.g. siRNAs
packaged into liposome or viral particles that
shield the siRNAs from recognition by the innate
immune system. Likewise, the recent findings do
not relate to gene therapy approaches in which
the siRNAs are expressed intracellularly, e.g. as
short hairpin RNAs (shRNA) against HIV-1.
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